close

Agreements

1 226 227 228 229 230 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2012-01-09 Xenon Pharmaceuticals (USA) Genentech, a member of the Roche Group (USA - Switzerland) compounds and companion diagnostics for the potential treatment of pain pain CNS diseases
2012-01-09 Leo Pharma (Denmark) Virobay (USA) undisclosed compound psoriasis development
licensing
Autoimmune diseases - Dermatological diseases
2012-01-06 AnaptysBio (USA) Novartis (Switzerland) therapeutic antibodies to multiple oncology-related therapeutic targets. cancer R&D Cancer Oncology
2012-01-05 Octoplus (The Netherlands) undisclosed top-5 pharmaceutical company controlled release formulation that combines the client\'s optimized product candidate with Octoplus\'s proprietary drug delivery technology PolyActive undisclosed R&D
2012-01-05 Boehringer Ingelheim (Germany) FORMA Therapeutics (USA) small molecule drugs against oncology-relevant protein-protein interactions cancer R&D Cancer Oncology
2012-01-05 Midatech (UK) MonoSol Rx (USA) diabetes

joint-venture
licensing
commercialisation

Metabolic diseases Joint-venture agreement
2012-01-05 GSK (UK) ChemoCentryx (USA - CA) CCX354 rheumatoid arthritis Autoimmune diseases – Inflammatory diseases - Rheumatic diseases Exercise of an option agreement
2012-01-04 AM-Pharma (The Netherlands)

nomination

Inflammatory diseases Nomination
2011-12-22 Vivalis (France) undisclosed animal health company EB66® cell line for the production of several animal health vaccine licensing Veterinary medicine
2011-12-21 Arecor (UK) Eli Lilly (USA) stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly R&D
2011-12-20 Genmab (Denmark) - undisclosed pharma company DuoBody™ Platform

solid tumors

R&D Cancer Oncology
2011-12-20 Affibody (Sweden) Nuclisome (Sweden) new cancer therapeutics cancer R&D Cancer Oncology
2011-12-19 Summit (UK) Muscular Dystrophy Association (USA) Parent Project Muscular Dystrophy (USA) Charley’s Fund (USA) Cure Duchenne (USA) Foundation to Eradicate Duchenne (USA) Nash Avery Foundation (USA) SMT C1100 Duchenne muscular dystrophy Genetic diseases - Neuromuscular diseases - Rare diseases Establishment of a new subsidiary in the EU
2011-12-19 Amgen (USA - CA) Watson Pharmaceuticals (USA - NJ), now Actavis (Ireland), now Allergan (Ireland) oncology biosimilar products

development

commercialisation

Cancer - Oncology Development agreement
2011-12-16 Pharming (The Netherlands) Renova Life (USA) development and supply of founder transgenic rabbits hemophilia A

services

Hematological diseases - Genetic diseases - Rare diseases Services contract
2011-12-16 Transgene (France) French League against Cancer (France) new anticancer biotherapies cancer

R&D

Cancer - Oncology R&D agreement
2011-12-16 GSK (UK) GAVI Alliance pneumococcal vaccine, Synflorix® pneumococcal disease

supply

Infectious diseases Collaboration agreement
2011-12-15 Morphosys (Germany) Novozymes (Denmark) Slonomics technology

licensing
technology transfert

Licensing agreement
2011-12-15 GSK (UK) The University of Dundee (UK) Huntington’s disease

R&D

Rare diseases - Genetic diseases - Neurodegenerative diseases R&D agreement
2011-12-15 Shire (UK-USA) Atlas Venture (USA)

collaboration

Rare diseases Collaboration agreement